New York, Jan 19, 2026, 18:31 EST — The market has closed.
- Amgen shares closed Friday at $330.41, edging up roughly 0.1%
- U.S. stock markets remain closed Monday in observance of Martin Luther King Jr. Day; trading picks back up Tuesday
- Amgen’s quarterly results, due early February, are the next big catalyst—investors will be watching closely for updates on its obesity-drug efforts
Amgen shares closed Friday up roughly 0.1%, settling at $330.41, with U.S. markets shuttered Monday for Martin Luther King Jr. Day. (New York Stock Exchange)
The holiday lull offers investors limited new price moves, yet activity remains brisk. Amgen approaches earnings season, with traders eager for clearer signs of growth beyond its established franchises.
This is crucial now since Amgen’s stock behaves like a mix: reliable cash returns on one hand, and a pipeline story on the other. A change in confidence about its upcoming drug lineup can swiftly shake investor valuations.
Last week, the company reported that an extension study of its experimental obesity drug MariTide showed patients maintaining weight loss with lower or less frequent dosing. BMO Capital Markets analyst Evan Seigerman described the update as promising but noted, “we await more detailed results for further clarity.” Meanwhile, Amgen R&D chief Jay Bradner declared the company “unambiguously in the lead” on once-monthly or less-frequent dosing. (Reuters)
MariTide is undergoing trials as both a monthly injection and a quarterly dose. Amgen is positioning it as a possible substitute for the weekly shots offered by bigger competitors. The company previously reported gastrointestinal side effects like vomiting during earlier studies and intends to start patients on lower doses that increase gradually.
Investors are now pushing for specifics. They want hard numbers—and a sharper sense of how tolerability compares in a market dominated by GLP-1 drugs, the hormone pathway behind top-selling weight-loss treatments.
Amgen’s earnings report is the next major event to watch, scheduled for Feb. 3 after the market closes, according to Nasdaq. (Nasdaq)
The call is set to shape near-term positioning, focusing on MariTide’s trial updates, guidance tone, and daily business trends. Traders will also tune in to Amgen’s take on competition and timelines—not just the headline weight loss numbers.
Investors will keep an eye on sales momentum in key brands, along with how the company handles pressure on older products amid rising competition in parts of big pharma. Amgen’s stock tends to move as much on its commentary about demand and pricing as on any individual clinical result.
Income remains a key factor. In December, Amgen announced a $2.52-per-share dividend for Q1 2026, payable on March 6 to shareholders registered by Feb. 13. (Amgen)
Yet the situation isn’t one-sided. Should MariTide’s more comprehensive data fall short on safety or durability, or if carving out a clear edge against established competitors proves tougher, the growth story could falter and the stock might slip back into “bond proxy” territory.
The market reopens Tuesday, with Amgen back in focus. All eyes remain on its Feb. 3 earnings and the guidance management will offer afterward.
